
A new diagnostic platform is able to screen and identify four different diseases—colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer’s disease—with little blood in an hour. The patent-pending technology was developed by a team of researchers led by at the University of Notre Dame.
The diagnostic platform was tested in a blind setting using 87 plasma samples from patient blood draws who were either healthy or had one of the four diseases. The platform was found to be 90 to 99 percent accurate for detecting the presence or absence of each disease type.
“We believe that if we can screen these diseases earlier, then patients may have a better chance at surviving,� said Chang, the Bayer Corporation Professor of Engineering in the at Notre Dame.
The study was funded by the National Institutes of Health and published by , a top-tier journal in the field of bioengineering.
How immunojanus particles detect disease
The disease detection platform works by detecting exosomes found in the blood, which carry proteins that can provide an early indication of disease. To detect these proteins, the Chang Lab created immunojanus particles, or tiny spheres that have two, distinct halves. One half is affixed with antibodies and the other is fluorescent.
To run a test, 10 microliters of blood is diluted with a saline solution and mixed with immunojanus particles for 10 to 60 minutes, allowing the immunojanus particles to fully disperse throughout the blood mixture. As the immunojanus particles disperse, the antibodies will lock onto the disease-specific proteins found on the surface of exosomes.
The blood mixture is then analyzed under a microscope. While the antibodies on the immunojanus particles are essential for capturing markers of disease, the fluorescent half is imperative for signaling to researchers when those markers are present.
Detecting cancer with high accuracy
When the blood mixture is analyzed under the microscope for a test, the immunojanus particles will have the appearance of stars twinkling in the night sky. Chang and his lab designed a proprietary computer program to analyze this movement using Brownian motion—or the random, erratic movement of microscopic particles suspended in fluid—to tell them if a disease marker is present.
“We had to overcome the interference issue, and immunojanus particles can because they are both sensitive and selective. Sensitive because we can detect a single exosome on an immunojanus particle from the blinking frequency, and selective because other small molecules do not produce a signal,� Chang said.
Not only is the blood test considered significantly more accurate than the leading exosome detection technology, the method is also intentionally fast and low-cost.